Please login to the form below

Not currently logged in
Email:
Password:

Vascepa

This page shows the latest Vascepa news and features for those working in and with pharma, biotech and healthcare.

The Midas Touch

The Midas Touch

New trial data finds that Vascepa reduces major adverse CV events by 25%. ... Well done Amarin. The practical lesson of Amarin’s Vascepa for the rest of us is hidden in plain sight.

Latest news

  • Amarin hits jackpot with astonishing heart benefits from fish oil product Amarin hits jackpot with astonishing heart benefits from fish oil product

    Vascepa's effects in patients already treated with statins to lower their LDL cholesterol, who had various cardiovascular risk factors, including persistent elevated trigylcerides. ... patient population with use of Vascepa 4 grams/day as compared to

  • Amarin sues FDA over off-label policy Amarin sues FDA over off-label policy

    the risk of heart disease, even though Vascepa itself has not yet been shown to achieve that objective in trials. ... In the meantime Vascepa is bringing in modest sales, with first-quarter turnover of around $15m, albeit up from $11m a year ago.

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the ... Sales of Vascepa were around $26m in 2013, its first year on

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    Advisory committee wants more data on Vascepa. Shares in Irish company Amarin Corp nosedived yesterday after a US Food and Drug Administration (FDA) advisory committee voted against approval of its fish ... By a 9-2 margin, the panel said it would not

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics